First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis
{{output}}
Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for multiple sclerosis (MS). While its efficacy has been attributed to early and sustained B cell depletion, emerging evidence suggests a broader... ...
